Roche Announces New Five-Year Data of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma
2024-12-09 · Chugai Pharmaceutical · original chugai-pharm.co.jp ↗
TOKYO, December 9, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release on December 8, regarding five-year data from POLARIX study of Polivy ® (generic name: polatuzumab vedotin) for previously untreated diffuse large B-cell lymphoma (DLBCL). The data was presented at the 66th American Society of Hematology (ASH) Annual Meeting. Please refer to the link below for details of the press release: Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma https://www.roche.com/media/releases/med-cor-2024-12-08 Trademarks used or mentioned in this release are protected by laws.
The release as fetched from its publisher. chugai-pharm.co.jp ↗